3-((2,4-bis((4-methoxybenzyl)oxy)benzyl)amino)benzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-((2,4-bis((4-methoxybenzyl)oxy)benzyl)amino)benzoic acid
• 英文别名: 3-[[2,4-Bis[(4-methoxyphenyl)methoxy]phenyl]methylamino]benzoic acid；3-[[2,4-bis[(4-methoxyphenyl)methoxy]phenyl]methylamino]benzoic acid
• 化学式: C₃₀H₂₉NO₆
• 分子量: 499.563
• InChiKey: JGCSLARSZZNHJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  37
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  86.2
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2,4-二羟基苯甲醛 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 30.42h， 生成 3-((2,4-bis((4-methoxybenzyl)oxy)benzyl)amino)benzoic acid
  参考文献：
  名称：

  2-苯基-4-羧基喹啉化学型的结构引导进化为 PPARα 选择性激动剂：眼血管疾病的新线索

  摘要：

  PPARα 的小分子激动剂为开发糖尿病视网膜病变和年龄相关性黄斑变性等眼血管疾病的非侵入性治疗提供了一条有前景的新途径。在此，我们报告了新鉴定的基于喹啉的 PPARα 激动剂 Y-0452 的初始结构-活性关系。初步计算研究得出这样的假设：Y-0452 喹啉系统的羧酸转座和解构将增强配体-蛋白质相互作用并更好地补充结合袋的性质。设计、合成并评估了 PPARα 激动作用的重点类似物子集。这项工作产生了两个关键观察结果：1) 与其他 PPARα 激动剂相反，贝特“头基”的掺入降低了 PPARα 选择性，反而提供了泛PPAR 激动剂；2) 计算模型揭示了 PPARα 中相对未开发的两亲性口袋，它提供了新的开发新型激动剂的机会。例如，化合物10表现 出比 Y-0452 (EC 50 = ∼50 µM)更有效的 PPARα 激动作用 ( EC 50  = ∼6 µM)，并且对 PPARα 的选择性比

  DOI：

  10.1016/j.bmcl.2018.03.010

文献信息

• Agonists of peroxisome proliferator-activated receptor alpha and methods of use
  申请人：The Board of Regents of the University of Oklahoma

  公开号：US11447452B2

  公开（公告）日：2022-09-20

  Benzyl derivative compounds having peroxisome proliferator-activated receptor α (PPARα) agonistic activity, compositions containing such compounds, and methods of their use in enhancing PPARα activity for treating diseases and/or conditions involving inflammation and/or angiogenesis, particularly ocular diseases and/or conditions such as but not limited to retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema are disclosed.

  本发明公开了具有过氧化物酶体增殖激活受体α（PPARα）激动活性的苄基衍生物化合物、含有此类化合物的组合物，以及将其用于增强 PPARα 活性以治疗涉及炎症和/或血管生成的疾病和/或病症的方法，特别是眼部疾病和/或病症，如但不限于视网膜炎症、视网膜新生血管、视网膜血管渗漏、早产儿视网膜病变、糖尿病视网膜病变、老年性黄斑变性和糖尿病黄斑水肿。
• WO2019178439A5
  申请人：——

  公开号：WO2019178439A5

  公开（公告）日：2022-03-15
• AGONISTS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AND METHODS OF USE
  申请人：The Board of Regents of the University of Oklahoma

  公开号：US20210024469A1

  公开（公告）日：2021-01-28

  Benzyl derivative compounds having peroxisome proliferator-activated receptor α (PPARα) agonistic activity, compositions containing such compounds, and methods of their use in enhancing PPARα activity for treating diseases and/or conditions involving inflammation and/or angiogenesis, particularly ocular diseases and/or conditions such as but not limited to retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema are disclosed.
• AGONISTS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR?) AND METHODS OF USE
  申请人：The Board of Regents of the University of Oklahoma

  公开号：US20220389036A1

  公开（公告）日：2022-12-08

  Benzyl derivative compounds having peroxisome proliferator-activated receptor α (PPARα) agonistic activity, kits and compositions containing such compounds, and methods of their use in enhancing PPARα activity for treating diseases and/or conditions involving inflammation and/or angiogenesis, particularly ocular diseases and/or conditions such as but not limited to retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema.
• [EN] AGONISTS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AND METHODS OF USE<br/>[FR] AGONISTES DU RÉCEPTEUR ALPHA ACTIVÉ PAR LE PROLIFÉRATEUR DE PEROXISOME ET PROCÉDÉS D'UTILISATION
  申请人：UNIV OKLAHOMA

  公开号：WO2019178439A1

  公开（公告）日：2019-09-19

  Benzyl derivative compounds having peroxisome proliferator- activated receptor α (PPARα) agonistic activity, compositions containing such compounds, and methods of their use in enhancing PPARα activity for treating diseases and/or conditions involving inflammation and/or angiogenesis, particularly ocular diseases and/or conditions such as but not limited to retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema are disclosed.